X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://endpts.com/exclusive-centrexions-knee-pain-drug-fails-two-phiii-studies-but-ex-pfizer-ceo-kindlers-biotech-might-still-ask-for-fda-nod/
https://www.fiercebiotech.com/biotech/ocuterra-snags-35m-for-phase-2-trial-eye-drop-former-allergan-ceo-as-chair
https://www.globenewswire.com/news-release/2019/12/03/1955486/0/en/Centrexion-Therapeutics-Announces-Issuance-of-U-S-Composition-of-Matter-Patent-for-Lead-Pipeline-Candidate-CNTX-4975.html
https://www.fiercebiotech.com/biotech/kindler-s-centrexion-restarts-ipo-bid-to-fund-phase-3-pain-trial
https://endpts.com/jeff-kindlers-centrexion-renews-bid-to-make-public-debut/
https://www.fiercebiotech.com/biotech/centrexion-farms-out-pain-med-to-lilly-for-47-5m-and-could-reap-much-more
https://endpts.com/a-bruised-eli-lilly-buys-rights-to-centrexion-early-stage-pain-drug-for-47-5m-upfront/
https://www.biospace.com/article/eli-lilly-in-licenses-non-opioid-compound-from-centrexion/
https://centrexion.com/wp-content/uploads/2018/07/FINAL-CNTX-CFO-Appointment-PR-073018.pdf
https://centrexion.com/wp-content/uploads/2018/06/2018-6-26-FINAL-Centrexion-Swedish-press-release-1.pdf
Market Place
Share 
